Aortic valve stenosis cardiac valvular disease
Conditions
Interventions
None listed
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Age > 18 years - Mild, moderate or Severe degenerative aortic valve stenosis as defined by transthoracic echocardiography according to the 2017 ESC/EACTS guidelines for the management of valvular heart disease. - for the control group: - 150 healthy subjects without aortic valve stenosis - 50 subjects with aortic valve stenosis due to congenital biscuspid valve
Exclusion criteria
Exclusion criteria: For patients and controls: - Active auto-inflammatory or auto-immune diseases - Anti-inflammatory drugs - Vaccination less than one month before inclusion - Bone marrow transplantation - Active malignancy, except for local basal cell carcinoma or local squamous cell skin carcinoma, that can be treated curatively by excision. - History of endocarditis of the aortic valve - History of radiation therapy aimed at the chest - Acute ischemic cardiac event less than three months before inclusion - Systemic inflammation less than one month before inclusion with fever and/or for which antibiotics have been prescribed, with the exception for the use of nitrofurantoin for a urinary tract infection without fever. Extra exclusion for healthy control subjects: - History of atherosclerotic cardiovascular events - Current typical complaints of angina pectoris or intermittent claudication. - Overt heart failure (NYHA class III/IV) - Aortic valve stenosis on screenings echocardiography, that will be performed before inclusion. Mild aortic valve sclerosis is allowed. Extra exclusion for controls with aortic valve stenosis due to a bicuspid valve: - History of atherosclerotic cardiovascular events - Current typical complaints of angina pectoris or intermittent claudication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of CHIP driver mutations in blood cells. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoint is cytokine production capacity of isolated innate immunce cells. Other explorative endpoints include leukocyte composition,cytokine production capacity and ROS production of isolated neutrophils, circulating markers of inflammation, including cytokines and chemokines, circulating metabolome and proteome, deep transcriptional phenotyping of circulating monocytes and neutrophils is a subgroup of patients (from all subjects, these cells will be isolated and stored in liquid nitrogen), detection of epigenetic markers, as a marker for trained immunity, on a selection of samples, histopathological examination of (a selection of) sugically removed valvular tissue. The researcher will call all participants after 2 and 5 year and check medical files to be able to explore whether the immunological parameters are associated with incident cardiovascular events and disease progression. | — |
Countries
Netherlands
Outcome results
None listed